The December 2026 DEA Telehealth Deadline: What It Means for TRT and HRT Prescribing

A Deadline That Keeps Getting Pushed, Except This Time It Might Not

Telehealth made TRT and HRT dramatically more accessible over the last several years, largely because a specific set of pandemic-era DEA rules let a prescriber skip the in-person exam the law otherwise requires before prescribing a controlled substance. Those flexibilities have already been extended four times.

The current extension runs through December 31, 2026. DEA has reportedly been working toward a permanent framework, but "reportedly close" is not the same as finalized, and this is not the first deadline that looked likely to arrive without a permanent fix in place. A clinic running a telehealth hormone program needs a real plan for the flexibility actually expiring, not a bet on which outcome lands first.

Where This Rule Actually Comes From

The underlying law is the Ryan Haight Online Pharmacy Consumer Protection Act, passed in 2008, which generally requires a prescriber to have conducted at least one in-person medical evaluation of a patient before prescribing a controlled substance — closing a gap that had let online operations dispense controlled medications off a questionnaire alone.

COVID-19 public health emergency waivers suspended that in-person requirement, and DEA and HHS have kept extending those waivers well past the end of the emergency itself. The current one is a fourth temporary extension, running through December 31, 2026, and it applies to Schedule II through V controlled substances prescribed via telehealth.

Why This Splits Hormone Therapy Into Two Different Questions

Testosterone is a Schedule III controlled substance under federal law, which puts testosterone-based TRT and masculinizing HRT squarely inside the rule this deadline governs. If the flexibility genuinely expires without a permanent replacement, prescribing or renewing a testosterone prescription by telehealth alone — without the patient having had a qualifying in-person exam with the prescribing physician or a referring one — stops being a gray area.

Estrogen, progesterone and spironolactone, the core of feminizing hormone therapy, are not controlled substances at all. This specific DEA rule does not touch them. That does not mean feminizing HRT is unregulated by telehealth generally — ordinary state medical board rules on telehealth exams still apply — but it is a genuinely separate compliance question from the one this deadline raises.

• Testosterone-based care (TRT, masculinizing HRT): Schedule III controlled substance — directly governed by this deadline. Telehealth prescribing without a qualifying in-person exam becomes a real compliance problem if the flexibility lapses.
• Estrogen-based care (feminizing HRT): Estrogen, progesterone and spironolactone are not controlled substances. Unaffected by this specific rule, though ordinary state telehealth and exam requirements still apply.

What Happens After December 31, 2026

Two real outcomes are on the table, and planning around only the optimistic one is how a clinic ends up out of compliance the first week of January.

• If the flexibility genuinely expires: a telehealth TRT program needs a qualifying in-person exam — its own, or a documented referral — before a new or renewal testosterone prescription can be written by telehealth alone. Clinics without that pathway already built face a real disruption, not a paperwork inconvenience.
• If DEA finalizes a Special Registration framework first: a subset of vetted telehealth prescribers could continue prescribing controlled substances without the in-person requirement, under whatever conditions DEA actually attaches to that registration — conditions that have not been published in final form as of this writing.

What a Telehealth TRT or HRT Clinic Should Actually Do Now

• Build the in-person exam pathway before you need it: a real relationship with a local physician network, or your own in-person capacity, that can perform the qualifying exam — not a plan to figure it out in December.
• Document every existing testosterone patient's exam history now: so you know today which patients already have a qualifying in-person exam on file and which ones would need one if the flexibility lapses, rather than discovering the gap after the deadline.
• Keep the two hormone categories on separate compliance tracks: a blanket "telehealth hormone therapy" protocol that treats testosterone and estrogen-based care identically is exactly the kind of gap this deadline exposes.
• Watch the Special Registration rule, but don't plan around it: build your compliance plan for the flexibility actually expiring, and treat a finalized Special Registration framework as upside if it lands in time — not the plan itself.

Where MedGrid Fits

This is exactly the kind of regulatory shift a real chart-review cadence exists to catch. Your medical director reviews which patients in a telehealth hormone program actually have a qualifying exam on file, helps build the referral or in-person pathway before the deadline forces it, and keeps testosterone-based and estrogen-based protocols on the separate tracks they actually require — see our HRT and TRT program page for how standing orders and monitoring cadence get built for this category specifically.

Frequently Asked Questions

• Does this affect estrogen, progesterone or spironolactone prescribing?: No — none of those are controlled substances, so this specific DEA rule does not apply to them. Standard state telehealth and exam rules still govern feminizing HRT, but this particular deadline is not one of them.
• Is the December 31, 2026 deadline final?: It is the date the current, fourth temporary extension runs through. DEA has extended these flexibilities multiple times already and is reportedly working on a permanent framework, but neither a further extension nor a final rule is guaranteed before the date arrives.
• What is the DEA Special Registration pathway?: A proposed permanent framework that would let vetted telemedicine providers prescribe controlled substances without a prior in-person exam, under specific oversight conditions. It has not been finalized as of this writing, so a compliance plan should not depend on it existing in time.
• Can a nurse practitioner or PA prescribe testosterone by telehealth under this rule?: The same in-person exam requirement applies to whichever practitioner holds the DEA registration and prescribing authority for that patient — the rule is about the prescribing relationship and modality, not limited to physicians specifically.

This article reflects the DEA/HHS telemedicine flexibility extension in effect as of publication and general information about the Ryan Haight Act, not legal advice for your specific practice. Federal telehealth prescribing rules are actively changing and could be extended, replaced or allowed to lapse before this deadline arrives — confirm current status with your medical director and licensed counsel before relying on any particular outcome.